Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities.

De, D; Kaushik, A; Handa, S; Mahajan, R; Schmidt, E

De, D; Kaushik, A; Handa, S; Mahajan, R; Schmidt, E.

Afiliação

De D; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Kaushik A; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Handa S; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Mahajan R; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Schmidt E; Department of Dermatology, University of Lübeck, Lübeck, Germany.

J Eur Acad Dermatol Venereol ; 35(7): e469-e472, 2021 Jul.

Article em En | MEDLINE | ID: mdl-33725360

Assuntos

Antialérgicos; Penfigoide Bolhoso; Antialérgicos/uso terapêutico; Humanos; Imunoglobulina E; Morbidade; Omalizumab/uso terapêutico; Penfigoide Bolhoso/tratamento farmacológico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Penfigoide Bolhoso / Antialérgicos Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Índia País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google